CDKN2A and neoplasm: Deng C et al. demonstrated that CDKN2A mutations (e.g., deletions, point mutations) in GA suppress interferon-α/γ responses, inflammatory reactions, and other immune-related pathways, impairing anti-tumor immunity and correlating with shorter patient survival [36].